1. Home
  2. SPFI vs DSGN Comparison

SPFI vs DSGN Comparison

Compare SPFI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo South Plains Financial Inc.

SPFI

South Plains Financial Inc.

HOLD

Current Price

$44.75

Market Cap

794.2M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$12.29

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPFI
DSGN
Founded
1941
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
794.2M
853.8M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
SPFI
DSGN
Price
$44.75
$12.29
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$46.00
$15.25
AVG Volume (30 Days)
144.1K
636.8K
Earning Date
04-28-2026
04-28-2026
Dividend Yield
1.68%
N/A
EPS Growth
17.81
N/A
EPS
0.85
N/A
Revenue
N/A
N/A
Revenue This Year
$22.65
N/A
Revenue Next Year
$9.40
N/A
P/E Ratio
$52.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.34
$3.85
52 Week High
$46.94
$17.25

Technical Indicators

Market Signals
Indicator
SPFI
DSGN
Relative Strength Index (RSI) 55.53 47.48
Support Level $39.06 $11.65
Resistance Level $44.48 $13.54
Average True Range (ATR) 1.37 0.82
MACD 0.02 -0.10
Stochastic Oscillator 48.38 32.14

Price Performance

Historical Comparison
SPFI
DSGN

About SPFI South Plains Financial Inc.

South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: